TDP-43 and Alzheimer's Disease Pathologic Subtype in Non-Amnestic Alzheimer's Disease Dementia.

BACKGROUND TDP-43 has been shown to be strongly associated with memory loss, smaller hippocampal volumes, and faster rates of hippocampal atrophy in Alzheimer's disease (AD) patients with an amnestic presentation. Whether TDP-43 has any clinical or anatomical associations in AD patients with non-amnestic phenotype is unknown. OBJECTIVE To determine whether TDP-43 plays a significant role in the clinic-anatomic features of non-amnestic AD. METHODS All cases with pathologically confirmed intermediate-high probability AD from 1996-2012 were identified and retrospectively sub-classified into amnestic versus non-amnestic dementia at the time of presentation. Neurofibrillary tangle counts were performed in those with a non-amnestic presentation using thioflavin-S microscopy in the hippocampus and three neocortical regions, and all cases were subtyped into hippocampal-sparing, limbic-predominant, and typical AD pathology. TDP-43 immunoreactivity was used to assess for the presence of TDP-43. Statistical analyses helped determine whether pathologic subtype or TDP-43 was more strongly associated with clinico-imaging features. RESULTS Out of 172 pathologically confirmed AD cases, 36 (19%) were classified as non-amnestic. Twenty-five of these 36 (69%) had typical pathology, 0 limbic-predominant pathology, and 11 (31%) hippocampal-sparing pathology. Eleven (44%) of the 25 cases with typical pathology were TDP-43+. Of the 11 cases with hippocampal-sparing pathology, 4 (36%) were TDP-43+. There were no differences in demographic, clinical, or neuroimaging features in those with TDP-43 versus those without except for older age at onset (p = 0.02) and age at death (p = 0.02) in those with TDP-43. AD pathological subtype accounted for slightly more of the variances in the neocortex than TDP-43. CONCLUSION In non-amnestic AD, we find little evidence that clinical or anatomical features of the disease are related to TDP-43.

[1]  C. Jack,et al.  Rates of hippocampal atrophy and post-mortem TDP-43 in Alzheimer’s disease: a longitudinal retrospective study , 2017, The Lancet Neurology.

[2]  Charles D. Smith,et al.  “New Old Pathologies”: AD, PART, and Cerebral Age-Related TDP-43 With Sclerosis (CARTS) , 2016, Journal of neuropathology and experimental neurology.

[3]  Jennifer L. Whitwell,et al.  Updated TDP-43 in Alzheimer’s disease staging scheme , 2016, Acta Neuropathologica.

[4]  L. Petrucelli,et al.  TAR DNA‐binding protein 43 and pathological subtype of Alzheimer's disease impact clinical features , 2015, Annals of neurology.

[5]  Nick C Fox,et al.  Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria , 2014, The Lancet Neurology.

[6]  C. Jack,et al.  TDP-43 is a key player in the clinical features associated with Alzheimer’s disease , 2014, Acta Neuropathologica.

[7]  C. Jack,et al.  Staging TDP-43 pathology in Alzheimer’s disease , 2014, Acta Neuropathologica.

[8]  D. Bennett,et al.  TDP-43 pathology, cognitive decline, and dementia in old age. , 2013, JAMA neurology.

[9]  C. Jack,et al.  Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: a case-control study , 2012, The Lancet Neurology.

[10]  Jason D. Warren,et al.  Alzheimer's pathology in primary progressive aphasia , 2012, Neurobiology of Aging.

[11]  Nick C Fox,et al.  Posterior cortical atrophy , 2012, The Lancet Neurology.

[12]  H. Akiyama [CERAD (The Consortium to Establish a Registry for Alzheimer's Disease) criteria]. , 2011, Nihon rinsho. Japanese journal of clinical medicine.

[13]  R. Petersen,et al.  Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study , 2011, The Lancet Neurology.

[14]  D. Dickson,et al.  TDP-43 in aging and Alzheimer's disease - a review. , 2011, International journal of clinical and experimental pathology.

[15]  Nancy Johnson,et al.  TDP-43 pathology in primary progressive aphasia and frontotemporal dementia with pathologic Alzheimer disease , 2010, Acta Neuropathologica.

[16]  Sébastien Ourselin,et al.  Progressive logopenic/phonological aphasia: Erosion of the language network , 2010, NeuroImage.

[17]  B. Miller,et al.  The logopenic/phonological variant of primary progressive aphasia , 2008, Neurology.

[18]  C. Jack,et al.  Abnormal TDP-43 immunoreactivity in AD modifies clinicopathologic and radiologic phenotype , 2008, Neurology.

[19]  C. Jack,et al.  11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. , 2008, Brain : a journal of neurology.

[20]  Gerald van Belle,et al.  Consortium to Establish a Registry for Alzheimer’s Disease (CERAD): The first twenty years , 2008, Alzheimer's & Dementia.

[21]  J. Morris,et al.  Clinical and psychometric distinction of frontotemporal and Alzheimer dementias. , 2007, Archives of neurology.

[22]  D Harrich,et al.  Cloning and characterization of a novel cellular protein, TDP-43, that binds to human immunodeficiency virus type 1 TAR DNA sequence motifs , 1995, Journal of virology.

[23]  M. Mendez,et al.  Pick's disease versus Alzheimer's disease , 1993, Neurology.